Evidence map›Paper›PMID 41117924›Full record

ArticleClinical and experimental medicine2025

Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Maha Elsabaawy, Amr Ragab, Amal Abd-Elrazek, Mohamed Atef, Madiha Naguib

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Evaluation of Sarcopenic Obesity in Patients with MASLD.Medical sciences (Basel, Switzerland) · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maha ElsabaawyDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt. maha.ahmed@liver.menofia.edu.eg.
Amr RagabDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.
Amal Abd-ElrazekDepartment of Radiodiagnosis and Interventional Radiology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.
Mohamed AtefDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.
Madiha NaguibDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenic visceral obesity (SVO) has emerged as a high-risk metabolic phenotype in metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to define the prevalence and metabolic implications of MRI-defined SVO in MASLD, evaluate its association with liver fibrosis, cardiovascular risk, and introduce a novel tier-based classification for risk stratification. In this cross-sectional study, 334 adults with MASLD underwent comprehensive phenotyping. Sarcopenia was assessed by bioelectrical impedance analysis, while visceral obesity was quantified via MRI-based visceral fat area (VFA ≥ 100 cm

Indexed as

Fatty LiverObesity, AbdominalSarcopeniaAdultAgedCross-Sectional StudiesElasticity Imaging TechniquesFemaleHumansLiver CirrhosisMagnetic Resonance ImagingMaleMiddle AgedPrevalenceBody compositionCardiovascular riskLiver fibrosisMASLDMRISarcopenic obesityTier classificationVisceral fat

Identifiers

PMID41117924
PMCPMC12540545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.